Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin

• Published in: Antiviral therapy Vol. 9; no. 4; pp. 505 - 509
• Main Authors: Soriano, Vincent, Núñez, Marina, Camino, Nuria, Maida, Ivana, Barreiro, Pablo, Romero, Miriam, Martín-Carbonero, Luz, Garcia-Samaniego, Javier, González-Lahoz, Juan
• Format: Journal Article
• Language: English
• Published: London International Medical Press 01.08.2004
• Subjects: Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biological and medical sciences; Drug Therapy, Combination; Female; Genotype; Hepacivirus - genetics; Hepacivirus - isolation & purification; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; HIV Infections - complications; HIV Infections - drug therapy; Humans; Interferon-alpha - administration & dosage; Interferon-alpha - therapeutic use; Male; Medical sciences; Pharmacology. Drug treatments; Predictive Value of Tests; Recurrence; Ribavirin - administration & dosage; Ribavirin - therapeutic use; RNA, Viral - blood; Immunopathology; Drug combination; Mixed infection; RNA; Cytokine; Hepatic disease; AIDS; Clearance; Immune deficiency; Ribavirin; Infection; Virus; Chronic; Viral disease; Antiviral; Digestive diseases; Interferon; Nucleosidic analog; Flaviviridae; Pegylated form; Hepatitis C virus; Hepacivirus; Viral hepatitis C

Hepatitis C virus (HCV)-RNA clearance seems to occur more slowly in HIV/HCV-coinfected patients than in HCV-monoinfected subjects treated with pegylated interferon alpha (peg-IFN) plus ribavirin (RBV). As a consequence, concern has arisen over the feasibility of following the treatment rules applied...